Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs
Explore this paper's citation graph
Summary
The limitations in efficacy and safety associated with available treatments for NSCLC underscore the need for novel agents with improved efficacy andSafety profiles and new agents in clinical development for this disease are discussed.
- Type
- review
- Published
- 2009-08-14
- Cited by
- 76
- References
- 81
- Access
- Open access
- OpenAlex
- https://openalex.org/W1973615073
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:20791658
Keywords
Lung cancer, Disease, Cancer, Chemotherapy, Intensive care medicine
References
- Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance.
- Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
- A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
- SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.
- High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
- Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer.
- Chemotherapy‐induced neutropenia
- Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma.
- Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
- Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial
- Epidermal growth factor receptor mutations in lung cancer
- 1104. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC)
- Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
- Alteration of Pemetrexed Excretion in the Presence of Acute Renal Failure and Effusions: Presentation of a Case and Review of the Literature
- Lung cancer--time to move on from chemotherapy.
- EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
- B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
- Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
- Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
Cited by
- Phytochemical screening, cytotoxicity and anticancer activity of Lobostemon fruticosus extracts on human lung cancer cell line
- Investigating the cancer stem cell hypothesis in canine tumours
- NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway
- Porous PLGA microparticles to encapsulate doxorubicin and polyethylenimine/miR-34a for inhibiting the proliferation and migration of lung cancer
- An indolylquinoline derivative promotes apoptosis in human lung cancer cells by impairing mitochondrial functions
- A novel synthetic analog of Militarin, MA-1 induces mitochondrial dependent apoptosis by ROS generation in human lung cancer cells.
- Effect of cigarette smoking on human health and promising remedy by mangroves
- Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer.
- Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches
- THE PROGNOSTIC ROLE OF ERCC1 IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW & META-ANALYSIS
- The Cell’s Nucleolus: an Emerging Target for Chemotherapeutic Intervention
- MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
- Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.
- Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets.
- Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
- Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
- Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer.
- GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation
- Cyanobacterial Cyclopeptides as Lead Compounds to Novel Targeted Cancer Drugs
- Pulmonary Drugs and Genes Delivery Systems for Lung Disease Treatment
Related papers
- Molecular Epidemiology of Female Lung Cancer
- Electrochemical biosensors for the detection of lung cancer biomarkers: A review.
- The Expression and Clinical Significance of Adrenomedulin in Patients with Lung Cancer
- Chemoprevention of lung cancer.
- 肺癌的性别差异及机制
- Molecular genetics of lung cancer in people who have never smoked.
- A Review of the Statistical Evidence on the Association Between Smoking and Lung Cancer
- Abstract B31: Gene-based lung cancer risk test (Respiragene), identifies high-risk smokers for early detection of lung cancer
- CHL1 gene polymorphisms increase lung cancer susceptibility